Figure 2.

Cumulative cervical cancer cases averted by 2068, 2088, and 2108 for alternative mitigation strategies among new adopter countries by eligible age group(s) at program introduction (single-age cohort for girls aged 9 years [left panel] or additionally providing a multi-age cohort for girls aged 10-14 years [right panel]) averaged across the Harvard and human papillomavirus (HPV)–ADVISE models (error bars reflect the minimum and maximum across the 2 models). An inferior 1-dose HPV vaccine is assumed to provide an average of 30 years (standard deviation = 5 years) of protection under no mitigation, a 2-dose single-age cohort mitigation, and a 2-dose multi-age cohort mitigation. 1D = 1-dose; 2D = 2-dose; MAC = multi-age cohort; SAC = single-age cohort.